A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS)
Authors
Jay L. Koyner (ORCID: https://orcid.org/0000-0001-6873-8712)
Christine M. Solinsky
Andrew Shaw (ORCID: https://orcid.org/0000-0002-0566-8005)
Alexander Zarbock (ORCID: https://orcid.org/0000-0002-2124-1714)
Kent Doi (ORCID: https://orcid.org/0000-0002-0115-1439)
William T. Smith (ORCID: https://orcid.org/0000-0002-9983-9193)
Pamela D. Winterberg (ORCID: https://orcid.org/0000-0002-8555-2837)
A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS)
Jay L. Koyner, Christine M. Solinsky, Andrew Shaw, Alexander Zarbock et al.
Citations
2 citations
Journal
Trials
Topics
Mechanical Circulatory Support Devices
Field-Weighted Citation Impact (FWCI)
1.35
article
A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS)
Jay L. Koyner, Christine M. Solinsky, Andrew Shaw, Alexander Zarbock, Kent Doi, William T. Smith, Pamela D. Winterberg, G. Li, Marlies Ostermann, David Corteville, Ravindra L. Mehta, Patrick Murray, Andre L. Lamy, Daniel T. Engelman
article en
2 citations
Abstract
No abstract available for this paper.
Publication Tag
TrialsVol. 26(1)
Institutions
University College Dublin (IE), Novartis (Switzerland) (CH), Cleveland Clinic (US), University of San Diego (US), University of Münster (DE), Population Health Research Institute (CA), University of Chicago (US), Unity Health System (US), University of Tokyo Hospital (JP), Verve Therapeutics (United States) (US), Baystate Health (US), Alexion Pharmaceuticals (United States) (US), AstraZeneca (United States) (US), Abiomed (United States) (US), Resuscitation Council (GB)